Syngene International Gears Up for Q3 Reveal on 17th January; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 9 Jan 2026 • 6:57 pm
Posted by:
Syngene International Q3 Results: one of the most significant Indian conglomerates, is set to announce its Q3 results for FY26 on 17th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Syngene International Q3 Results 2026 Preview
- Syngene International's revenue is expected to be in the range of ₹1,000 crore to ₹1,050 crore, with a 10% YoY increase.
- Profit After Tax (PAT) is projected to grow by 8% YoY to ₹170-₹180 crore.
- Syngene International's EBITDA is expected to rise 9% YoY to ₹300 crore.
- Net profit at ₹175 crore, up by 8% YoY
Syngene International Share Performance
- Over the past six months, Syngene International's share price has risen by 4.5% to ₹675.
- Moreover, over the past year, the stock has increased by 6.2%.
- Despite this weak short-term performance, Syngene International stock has delivered a financially sound 85% return over the past 5 years.
- As of 9th January 2026, the stock traded at ₹675 per share, with a day high of ₹690 per share.
Key Factors to Watch for Syngene International
- Revenue Growth & Client Pipeline: Demand from global pharma and biotech companies across discovery, development, and manufacturing services
- Order Book & Long-Term Contracts: New project additions and visibility from multi-year CRAMS agreements
- EBITDA & Margin Performance: Impact of operating leverage, input costs, and capacity utilisation
- Profit After Tax (PAT) Trend: YoY and QoQ profitability driven by execution efficiency
- Business Segment Performance: Growth momentum in discovery services, biologics, and dedicated research centres (DRCs)
Final Thoughts
Syngene International is expected to post steady Q3 FY26 performance, with ~10% revenue growth, 8% PAT growth, and stable margins. Continued focus on long-term client contracts, biologics expansion, and global pharma partnerships should support earnings visibility in FY26 and beyond.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Dev Accelerator IPO GMP & Review: Apply or Avoid?
Recent Articles
TSMC Stock Decoded: Can the Taiwan Chipmaker Reach a $6.5 Trillion Valuation by 2030, Nearly Tripling From Today, and Is It a Buy for the Next Four Years?
2 November 2026
EAAA India Alternatives IPO Listing: Shares Debut at 0.63% Premium on NSE and BSE, Check Share Price
2 November 2026
ITI Share Price Hits 20% Upper Circuit at Rs 259.14 After Opening Flat: Up 111% in Five Years but Down 34% in a Year, So Is It Time to Book Profits or Hold?
2 November 2026
Sebi Backs Removal of LTCG for Foreign Investors, Says Report: What the Proposal Means, Why FPI Outflows Hit Rs 3.04 Lakh Crore in 2026 and What Changes for Indian Investors
2 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
TSMC Stock Decoded: Can the Taiwan Chipmaker Reach a $6.5 Trillion Valuation by 2030, Nearly Tripling From Today, and Is It a Buy for the Next Four Years?
EAAA India Alternatives IPO Listing: Shares Debut at 0.63% Premium on NSE and BSE, Check Share Price
ITI Share Price Hits 20% Upper Circuit at Rs 259.14 After Opening Flat: Up 111% in Five Years but Down 34% in a Year, So Is It Time to Book Profits or Hold?
Sebi Backs Removal of LTCG for Foreign Investors, Says Report: What the Proposal Means, Why FPI Outflows Hit Rs 3.04 Lakh Crore in 2026 and What Changes for Indian Investors
Binance Hack Explained: $6.3 Billion Stolen in 20 Minutes, About $3 Billion Frozen, FBI Names North Korea and What It Means for Bitcoin and Indian Crypto Investors
Popular this week
Sensex Options Hit a Record Daily Premium Turnover in October 2026, Up 53% to Rs 35,481 Crore, as Volatility Returned to Indian Markets
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times